Zymeworks Inc. (ZYME) · Sep 23, 2026 · Acquisition

Zymeworks closes Theravance deal as $350M secured debt raises the integration stakes

$929M acquisition — Previously announced transaction; $350M notes at 8.25%

Zymeworks has completed its Theravance acquisition, adding YUPELRI and royalty cash flows—but the deal closes with $350M of 8.25% secured debt.

Zymeworks is shifting from a mostly oncology-focused biotech toward a broader asset-and-royalty platform, pairing Ziihera and its development pipeline with commercial and near-commercial cash flows such as YUPELRI. That strategy—and the Theravance transaction itself—was already publicly laid out before this filing.

The acquisition is now real, not incremental news. Zymeworks completed the previously announced merger, with each Theravance ordinary share converted into $17.00 in cash plus one CVR. Because the deal was announced on June 29 and expected to close in the second half of 2026, completion is confirmation rather than a surprise.

Deal elementFiling detail
Cash consideration$17.00 per Theravance share
Senior secured notes$350 million
Interest rate8.25% fixed
MaturityDecember 31, 2036
Ampreloxetine license proceeds allocated to CVRs80%
First commercial-sale milestone$50 million
Ampreloxetine net sales allocated to CVRs10%

The strategic payoff is broader cash generation, but it comes with real financing weight. Theravance brings YUPELRI and royalty-related assets into Zymeworks’ portfolio, supporting the company’s stated goal of combining R&D with commercial and royalty cash flows. 〔0〕 The filing also confirms that the acquisition was funded partly with $350 million of senior secured notes carrying 8.25% interest and maturing in 2036. 〔1〕 〔2〕

The debt terms make execution more important than the headline suggests. The notes are guaranteed by Theravance subsidiaries and secured by a first-priority lien on substantially all of the issuers’ and guarantors’ personal-property assets, while the agreement restricts additional debt, liens, dispositions, restricted payments and amendments to certain covered agreements. 〔3〕 That does not invalidate the acquisition thesis, but it means the new cash-flow platform must perform well enough to carry a meaningful fixed financing burden.

The CVR preserves upside without making it dependable. Former Theravance holders receive 80% of net proceeds from any ampreloxetine monetization, a pro rata share of a $50 million first-sale milestone, and 10% of later net sales; however, the filing explicitly says CVR payments are highly speculative and may never occur. 〔4〕

Bottom line: This closes a previously expected transformation of Zymeworks into a more diversified cash-flow biotech. The business upside is now tangible, but the $350 million of expensive, broadly secured debt makes the value of the deal depend on successful integration and sustained performance from the acquired assets.

What to watch next

September 28 transaction-details conference call

Original filing on SEC EDGAR

More Zymeworks Inc. news

Zymeworks closes Theravance deal as $350M secured debt raises the integration stakes | ZYME Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.